This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation

This study has been completed.
Information provided by:
Movetis Identifier:
First received: September 24, 2009
Last updated: September 30, 2009
Last verified: September 2009
Objectives: To evaluate the clinical long-term safety and the tolerability, patient satisfaction, pharmacokinetics and use of pattern of prucalopride given in doses up to 4 mg per day to patients with chronic constipation (CC).

Condition Intervention Phase
Chronic Constipation Drug: Prucalopride Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Long-Term Tolerability, Safety, Patient Satisfaction, Pharmacokinetics, and Use Patterns of Oral Prucalopride Tablets in Patients With Chronic Constipation

Resource links provided by NLM:

Further study details as provided by Movetis:

Primary Outcome Measures:
  • Safety: adverse events, lab tests, vital signs, ECGs [ Time Frame: 24 months ]

Secondary Outcome Measures:
  • Efficacy: PAC-QOL self-administered questionnaire, Patient's pattern of use of prucalopride [ Time Frame: 24 months ]
  • Pharmacokinetics: Prucalopride plasmaconcentrations [ Time Frame: 24 months ]

Enrollment: 1775
Study Start Date: July 1998
Primary Completion Date: November 2000 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Prucalopride
    1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and non-pregnant, non breast-feeding female outpatients at least 18 years of age.
  2. Patient completed the entire treatment period of one of the following studies: PRU-USA-3, PRU-USA-11, PRU-USA-13, PRU-USA-21, PRU-USA-25, PRU-USA-27 or PRU-USA-28, or Patient participated in the re-treatment study PRU-USA-28 and did not qualify for Treatment period II after both washout periods.

Exclusion Criteria:

  1. Patient with impaired renal function
  2. Patient with clinically significant abnormalities of haematology, urinalysis, or blood chemistry.
  3. Female of childbearing potential without adequate contraceptive protection during the study.
  4. Patient who used an investigation drug other than prucalopride in the 30 days preceding the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00987844

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Principal Investigator: Michael Camilleri, MD Mayo Clinic
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Renate Specht Gryp, Movetis Identifier: NCT00987844     History of Changes
Other Study ID Numbers: PRU-USA-22
Study First Received: September 24, 2009
Last Updated: September 30, 2009

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms processed this record on September 21, 2017